References
1. Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott SJJotACoC.
Prevalence and trends of metabolic syndrome in the adult US population,
1999–2010. 2013;62(8):697-703.
2. Zhuo Q, Yang W, Chen J, Wang YJNRR. Metabolic syndrome meets
osteoarthritis. 2012;8(12):729.
3. Katzmarzyk PT, Pérusse L, Rice T, Rao DC, Bouchard C. Familial
aggregation of seven-year changes in blood pressure in Canada. The
Canadian journal of cardiology. 2001;17(12):1267-1274.
4. Monda KL, North KE, Hunt SC, Rao DC, Province MA, Kraja AT. The
genetics of obesity and the metabolic syndrome. Endocrine,
metabolic & immune disorders drug targets. 2010;10(2):86-108.
5. Pérusse L, Després JP, Tremblay A, et al. Genetic and environmental
determinants of serum lipids and lipoproteins in French Canadian
families. Arteriosclerosis (Dallas, Tex). 1989;9(3):308-318.
6. Wang H, Dong S, Xu H, Qian J, Yang JJMbr. Genetic variants in FTO
associated with metabolic syndrome: a meta-and gene-based analysis.
2012;39(5):5691-5698.
7. Jin Y, Lee S-J, Minshall RD, Choi AMJAJoP-LC, Physiology M.
Caveolin-1: a critical regulator of lung injury. 2011;300(2):L151-L160.
8. Pavlides S, Gutierrez-Pajares JL, Danilo C, Lisanti MP, Frank PG.
Atherosclerosis, caveolae and caveolin-1. In: Caveolins and
Caveolae. Springer; 2012:127-144.
9. Shyu HY, Chen MH, Hsieh YH, et al. Association of eNOS and Cav-1 gene
polymorphisms with susceptibility risk of large artery atherosclerotic
stroke. PloS one. 2017;12(3):e0174110.
10. Baudranda R. A prevalent caveolin-1 gene variant is associated with
the metabolic syndrome in Caucasians and Hispanics. 2015.
11. Pojoga LH, Underwood PC, Goodarzi MO, et al. Variants of the
caveolin-1 gene: a translational investigation linking insulin
resistance and hypertension. J Clin Endocrinol Metab.2011;96(8):E1288-1292.
12. Fernandez-Hernando C, Yu J, Davalos A, Prendergast J, Sessa WC.
Endothelial-specific overexpression of caveolin-1 accelerates
atherosclerosis in apolipoprotein E-deficient mice. The American
journal of pathology. 2010;177(2):998-1003.
13. Frank PG, Pavlides S, Cheung MW, Daumer K, Lisanti MP. Role of
caveolin-1 in the regulation of lipoprotein metabolism. American
journal of physiology Cell physiology. 2008;295(1):C242-248.
14. Haddad D, Al Madhoun A, Nizam R, Al-Mulla F. Role of Caveolin-1 in
Diabetes and Its Complications. Oxidative Medicine and Cellular
Longevity. 2020;2020:9761539.
15. Chen S, Wang X, Wang J, et al. Genomic variant in CAV1 increases
susceptibility to coronary artery disease and myocardial infarction.Atherosclerosis. 2016;246:148-156.
16. Mora-Garcia G, Gomez-Camargo D, Alario A, Gomez-Alegria C. A Common
Variation in the Caveolin 1 Gene Is Associated with High Serum
Triglycerides and Metabolic Syndrome in an Admixed Latin American
Population. Metab Syndr Relat Disord. 2018;16(9):453-463.
17. Nizam R, Al-Ozairi E, Goodson JM, et al. Caveolin-1 Variant Is
Associated With the Metabolic Syndrome in Kuwaiti Children. Front
Genet. 2018;9:689.
18. Hu FB, Rimm EB, Stampfer MJ, Ascherio A, Spiegelman D, Willett WC.
Prospective study of major dietary patterns and risk of coronary heart
disease in men. The American journal of clinical nutrition.2000;72(4):912-921.
19. Mohammadifard N, Sajjadi F, Maghroun M, Alikhasi H, Nilforoushzadeh
F, Sarrafzadegan N. Validation of a simplified food frequency
questionnaire for the assessment of dietary habits in Iranian adults:
Isfahan Healthy Heart Program, Iran. ARYA atherosclerosis.2015;11(2):139-146.
20. Razani B, Woodman SE, Lisanti MP. Caveolae: from cell biology to
animal physiology. Pharmacological reviews. 2002;54(3):431-467.
21. Czikora I, Feher A, Lucas R, Fulton DJ, Bagi Z. Caveolin-1 prevents
sustained angiotensin II-induced resistance artery constriction and
obesity-induced high blood pressure. Am J Physiol Heart Circ
Physiol. 2015;308(5):H376-385.
22. Daniel EE, Eteraf T, Sommer B, Cho WJ, Elyazbi A. The role of
caveolae and caveolin 1 in calcium handling in pacing and contraction of
mouse intestine. J Cell Mol Med. 2009;13(2):352-364.
23. Wang H, Wang AX, Liu Z, Chai W, Barrett EJ. The
trafficking/interaction of eNOS and caveolin-1 induced by insulin
modulates endothelial nitric oxide production. Molecular
endocrinology (Baltimore, Md). 2009;23(10):1613-1623.
24. Iggman D, Risérus U. Role of different dietary saturated fatty acids
for cardiometabolic risk. Clinical Lipidology. 2011;6(2):209-223.
25. Phillips CM. Nutrigenetics and metabolic disease: current status and
implications for personalised nutrition. Nutrients.2013;5(1):32-57.
26. Le Lay S, Li Q, Proschogo N, et al. Caveolin-1-dependent and
-independent membrane domains. Journal of lipid research.2009;50(8):1609-1620.
27. Perona JS. Membrane lipid alterations in the metabolic syndrome and
the role of dietary oils. Biochim Biophys Acta Biomembr.2017;1859(9 Pt B):1690-1703.
28. Chapkin RS, McMurray DN, Davidson LA, Patil BS, Fan YY, Lupton JR.
Bioactive dietary long-chain fatty acids: emerging mechanisms of action.The British journal of nutrition. 2008;100(6):1152-1157.
29. Pilch PF, Liu L. Fat caves: caveolae, lipid trafficking and lipid
metabolism in adipocytes. Trends Endocrinol Metab.2011;22(8):318-324.
30. Grayson TH, Chadha PS, Bertrand PP, et al. Increased caveolae
density and caveolin-1 expression accompany impaired NO-mediated
vasorelaxation in diet-induced obesity. Histochemistry and cell
biology. 2013;139(2):309-321.
31. Su X, Abumrad NA. Cellular fatty acid uptake: a pathway under
construction. Trends Endocrinol Metab. 2009;20(2):72-77.
32. Howitt L, Grayson TH, Morris MJ, Sandow SL, Murphy TV. Dietary
obesity increases NO and inhibits BKCa-mediated, endothelium-dependent
dilation in rat cremaster muscle artery: association with caveolins and
caveolae. Am J Physiol Heart Circ Physiol.2012;302(12):H2464-2476.